APICES CRO is pleased to announce its contribution to the CANTABRICO study. This is a Phase IIIb clinical trial in Small Cell Lung Cancer (SCLC), recently featured in the Elsevier Lung Cancer Journal.
The study evaluates first-line treatment in patients with extensive-stage SCLC (ES-SCLC) using an initial regimen of up to six cycles of durvalumab plus platinum-etoposide, followed by maintenance with durvalumab. The results demonstrate the feasibility of this approach. It also provides additional options for daily clinical management depending on patient characteristics.
APICES contributed to the study through start-up, coordination, project management, monitoring, data management, statistical analysis and medical editorial assistance. The work of Sofía Morante, Ana Moreno, Laura Redondo, Susana Vara, Fernando Rico-Villademoros, and Juan Luis Sanz, along with the broader Spanish team, has been instrumental in the success of this project.
We also acknowledge AstraZeneca Spain and Dr. Dolores Isla for the collaboration and opportunity to contribute to this important study advancing treatment options in oncology.
For further information about the CANTABRICO Clinical Trial, please read the full scientific publication following the link: Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial – Lung Cancer
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
